Menu
  • Join
  • Login
  • Contact
 

Search abstracts


CLINICAL IMPLICATIONS OF NIVOLUMAB IN CANCER IMMUNOTHERAPY

  • At: 2015 FIP Congress in Düsseldorf (Germany)
  • Type: Poster
  • By: KUCUK, Esra (Hacettepe University Faculty of Pharmacy, Clinical Pharmacy, Ankara, Turkey)
  • Co-author(s): Esra KUCUK
    Ecz. Burcu Kelleci, Hacettepe Universitesi Eczacilik Fakultesi Klinik Eczacilik Anabilim Dali
  • Abstract:

    A cancer treatment recently focuses on immunotherapy such as nivolumab, ipilimumab and pembrolizumab.

    We searched through the Pub-Med database (between 2010-2015) by using nivolumab and immunotherapy as keywords.

    Nivolumab is administered via iv infusion over an hour at the dose of 2-3mg/kg for every 2-3 weeks. Drug must be constituted with 0,9%

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses